Scientific Reports (Aug 2017)

Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells

  • Sandeep Kumar Vishwakarma,
  • Priyanka Sharmila,
  • Avinash Bardia,
  • Lakkireddy Chandrakala,
  • N. Raju,
  • G. Sravani,
  • B. V. S. Sastry,
  • Md Aejaz Habeeb,
  • Aleem Ahmed Khan,
  • Marshal Dhayal

DOI
https://doi.org/10.1038/s41598-017-08878-y
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 12

Abstract

Read online

Abstract The present study identifies the potential of highly biocompatible SF-GNP nano-conjugate to enhance the chemotherapeutic response to combat drug resistance in cancer cells. We developed a stable colloidal suspension of sorafenib-gold nanoconjugate (SF-GNP) of 80%) the percentage cell survival and the size and number of SF resistant solid tumor colonies of HepG2 cells in 3D model system. The exposure of SF-GNP nanoconjugate to SF resistant HepG2 cell colonies also provided evidence for anti-proliferative effect and reversal of drug resistance by elucidating the molecular regulatory mechanisms of extracellular matrix factor (CD147), tumor growth factor (TGF-β), hepatoma upregulated protein (hURP) and drug transporter (ABCG-2).